• Home
  1. Home
  2. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites
Scientific article
OA Policy
English

Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites

ContributorsMarsousi, Niloufar; Daali, Youssef; Fontana, Pierreorcid; Reny, Jean-Lucorcid; Ancrenaz, Virginie; Calmy, Alexandraorcid; Rudaz, Sergeorcid; Desmeules, Jules Alexandre; Samer, Caroline Floraorcid
Published inClinical Pharmacokinetics, vol. 57, no. 10, p. 1347-1354
Publication date2018
Abstract

Prasugrel and clopidogrel are inhibitors of the ADP-P2Y12 platelet receptor used in acute coronary syndrome patients. They require bioactivation via isoenzymes such as cytochrome P450 (CYP) 3A4, CYP2C19 and CYP2B6. Ritonavir and cobicistat are potent CYP3A inhibitors, prescribed as pharmacokinetic (PK) enhancers in the treatment of human immunodeficiency virus (HIV) infection.

Affiliation entities
Research groups
Citation (ISO format)
MARSOUSI, Niloufar et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. In: Clinical Pharmacokinetics, 2018, vol. 57, n° 10, p. 1347–1354. doi: 10.1007/s40262-018-0637-6
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN0312-5963
737views
842downloads

Technical informations

Creation11/13/2018 3:14:00 PM
First validation11/13/2018 3:14:00 PM
Update time02/03/2025 11:23:15 AM
Status update02/03/2025 11:23:15 AM
Last indexation08/18/2025 11:31:24 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack